A significant development in autoimmune disease treatment arrived in March 2026 when the U.S. Food and Drug Administration approved Sotyktu (deucravacitinib) for adults living with active psoriatic arthritis. The approval introduces a new oral therapy that targets a specific immune pathway linked to inflammation in both joints and skin.
Psoriatic arthritis is a chronic autoimmune condition that can lead to joint pain, stiffness, swelling, and fatigue. Many patients also experience psoriasis, a skin disease marked by red, scaly patches. Because the disease affects multiple parts of the body and can progress over time, effective treatments remain a major focus of medical research.
The newly approved therapy expands treatment options for patients and physicians. It also marks the first approval of a selective tyrosine kinase 2 inhibitor for psoriatic arthritis.
This article explains what psoriatic arthritis is, how Sotyktu works, clinical trial findings behind the FDA decision, safety considerations, and what the approval may mean for patients.
Psoriatic arthritis (PsA) is an immune mediated inflammatory disease that affects the joints and connective tissues. The condition commonly develops in individuals who already have psoriasis.
According to medical research and clinical reports, up to 30 percent of people with psoriasis may develop psoriatic arthritis at some point in their lives.
Symptoms vary widely but often include:
Inflammation may affect multiple areas of the body, including joints, tendons, and the places where ligaments attach to bones. This inflammation can eventually damage joints and limit movement if untreated.
Because the disease progresses differently in each patient, physicians often need multiple treatment approaches. These may include anti inflammatory drugs, biologic therapies, or disease modifying medications.
Despite available therapies, some patients continue to experience symptoms or cannot tolerate existing medications. That need for additional treatment options helped drive research leading to the development of Sotyktu.
Sotyktu is an oral prescription medication developed by Bristol Myers Squibb. It belongs to a class of drugs known as TYK2 inhibitors.
TYK2 stands for tyrosine kinase 2, a protein involved in signaling pathways that regulate immune system activity.
The medication selectively blocks TYK2 signaling pathways that are associated with inflammatory immune responses.
These pathways include signals triggered by immune molecules such as:
These molecules are believed to play key roles in the development of psoriasis and psoriatic arthritis. By limiting these signals, the medication may reduce inflammation in both skin and joints.
Unlike many injectable biologic therapies used for autoimmune diseases, Sotyktu is taken orally once daily, which may offer convenience for some patients.
Before receiving approval for psoriatic arthritis, Sotyktu was already approved in the United States in 2022.
That earlier approval covered adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Clinical trials in psoriasis demonstrated improvements in skin symptoms and quality of life measures. The drug has since been approved in multiple countries for that indication.
The new FDA approval expands its use to treat joint disease associated with psoriasis.
The FDA approval was based on results from two large phase 3 clinical trials:
Both studies evaluated the safety and effectiveness of once daily Sotyktu in adults with active psoriatic arthritis.
The trials included patients aged 18 years and older who met diagnostic criteria for psoriatic arthritis. Participants had at least three swollen joints and three tender joints and either active or historical plaque psoriasis.
Key aspects of the trials included:
The primary endpoint measured improvement in symptoms at week 16 using the ACR20 response, a standard measure used in rheumatology studies.
Both phase 3 trials showed that patients taking Sotyktu experienced significantly greater improvement than those receiving placebo.
In the trials:
ACR20 represents at least a 20 percent improvement in joint swelling, tenderness, and other disease activity measures.
Researchers also measured stronger response categories:
These higher scores represent deeper improvements in symptoms.
Another important outcome was minimal disease activity, meaning several symptoms improved simultaneously.
Results showed:
Beyond joint inflammation, the studies evaluated how treatment affected daily functioning and well being.
Researchers used the 36 Item Short Form Health Survey (SF-36), a widely used quality of life measurement tool.
Patients taking Sotyktu showed improvements in several physical health domains, including:
Improvements in these areas suggest the treatment may help patients maintain mobility and daily activity levels.
The safety profile observed in psoriatic arthritis trials was similar to earlier studies conducted in plaque psoriasis.
Reported side effects included:
These reactions occurred in at least 1 percent of patients receiving the medication.
Healthcare providers are advised to monitor patients for several potential risks, including:
Patients may require screening for infections such as tuberculosis before starting treatment.
Vaccination status should also be reviewed because live vaccines are generally avoided during therapy.
The newly approved therapy may benefit adults with active psoriatic arthritis, especially those who need additional treatment options.
Potential advantages may include:
However, treatment decisions must be individualized. Physicians typically evaluate several factors before prescribing a medication, including disease severity, medical history, and possible risks.
The approval also represents an important milestone in immunology research.
TYK2 inhibitors are a newer category of medications designed to selectively interfere with immune signaling pathways. Scientists hope these targeted therapies may provide effective treatment with fewer systemic effects compared with broader immune suppressing drugs.
Researchers continue to investigate TYK2 inhibitors for additional inflammatory conditions.
The ongoing clinical development of Sotyktu may include studies examining its role in other diseases where immune signaling pathways contribute to inflammation.
Participants who completed the initial 52 week treatment period in the phase 3 trials were eligible to enroll in extended follow up studies.
These extensions may continue monitoring patients for up to 156 weeks. Long term data will help researchers better understand safety, durability of response, and long term disease control.
Such information is essential because psoriatic arthritis is a lifelong condition that often requires extended treatment.
For many patients living with psoriatic arthritis, managing symptoms can involve years of trial and error with different medications.
New treatments offer hope for better disease control and improved quality of life. The availability of an oral TYK2 inhibitor provides another therapeutic approach that doctors may consider alongside biologics and other disease modifying drugs.
Although not every patient will respond to the same therapy, expanding the treatment landscape increases the chances that individuals can find an option that works for them.
The FDA approval of Sotyktu (deucravacitinib) for active psoriatic arthritis represents an important advancement in autoimmune disease treatment. As the first selective TYK2 inhibitor approved for this condition, the medication offers a new oral therapy targeting key immune pathways linked to inflammation.
Clinical trials demonstrated meaningful improvements in joint symptoms, disease activity, and quality of life measures compared with placebo. While safety monitoring remains important, the therapy provides another option for patients whose symptoms remain difficult to manage.
As research continues and long term data emerge, medications like Sotyktu may help reshape the way physicians treat psoriatic disease and related inflammatory conditions.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided should not replace consultation with a qualified healthcare professional. Patients should speak with their physician or other licensed healthcare provider regarding any medical condition or treatment decisions.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.